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Background: Severe shortage of liver donors and hepatocytes highlights urgent requirement of extra-liver and
stem cell source of hepatocytes for treating liver-related diseases. Here we hypothesized that spermatogonial stem
cells (SSCs) can directly transdifferentiate to hepatic stem-like cells capable of differentiating into mature
hepatocyte-like cells in vitro without an intervening pluripotent state.
Results: SSCs first changed into hepatic stem-like cells since they resembled hepatic oval cells in morphology and
expressed Ck8, Ck18, Ck7, Ck19, OV6, and albumin. Importantly, they co-expressed CK8 and CK19 but not ES cell
markers. Hepatic stem-like cells derived from SSCs could differentiate into small hepatocytes based upon their
morphological features and expression of numerous hepatic cell markers but lacking of bile epithelial cell hallmarks.
Small hepatocytes were further coaxed to differentiate into mature hepatocyte-like cells, as identified by their
morphological traits and strong expression of Ck8, Ck18, Cyp7a1, Hnf3b, Alb, Tat, Ttr, albumin, and CYP1A2 but not
Ck7 or CK19. Notably, these differentiated cells acquired functional attributes of hepatocyte-like cells because they
secreted albumin, synthesized urea, and uptake and released indocyanine green. Moreover, phosphorylation of
ERK1/2 and Smad2/3 rather than Akt was activated in hepatic stem cells and mature hepatocytes. Additionally,
cyclin A, cyclin B and cyclin E transcripts and proteins but not cyclin D1 or CDK1 and CDK2 transcripts or proteins
were reduced in mature hepatocyte-like cells or hepatic stem-like cells derived from SSCs compared to SSCs.
Conclusions: SSCs can transdifferentiate to hepatic stem-like cells capable of differentiating into cells with
morphological, phenotypic and functional characteristics of mature hepatocytes via the activation of ERK1/2 and
Smad2/3 signaling pathways and the inactivation of cyclin A, cyclin B and cyclin E. This study thus provides an
invaluable source of mature hepatocytes for treating liver-related diseases and drug toxicity screening and offers
novel insights into mechanisms of liver development and cell reprogramming.
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Liver cancer is one of most common tumors around the
world and the majority of patients with this disease usually
die within one year [1]. Hepatitis B virus infected over 300
million people, which is a common cause of end-stage
liver diseases including cirrhosis [2]. The effective treatment
for end-stage liver diseases is liver transplantation [3].
However, there is a severe shortage of liver donors,
which is the major obstacle for treatment of patients with
end-stage liver diseases. Consequently, many patients
suffering from end-stage liver diseases have to be on the
waiting list and they die before liver transplantation can be
performed. Hepatocytes’ transplantation is an alternative
approach to restore liver function and cure liver congenital
metabolic diseases [4,5]. Nevertheless, human hepatocytes
are scarce in number and have a very limited potential
of proliferation. Therefore, it is crucial to seek a readily
available source of hepatocytes from extra-liver tissues
and/or stem cells that can be cultured and expanded
in vitro to treat patients with end-stage liver diseases.
Hepatic stem cells can differentiate into functional
hepatocytes [6]. Nevertheless, the number of hepatic
stem cells is very few in patients with end-stage liver
diseases. Embryonic stem (ES) cells have been used to
differentiate into hepatocytes [7]. However, the availability
of human ES cells is rather limited due to the ethic and
safety issues [8]. Recently, the induced pluripotent stem
(iPS) cells have been utilized to generate functional hepato-
cytes [9,10]. Nevertheless, it is cautious to use hepatocytes
derived from iPS cells for clinical applications due to
their genetic instability and using viral transduction for
reprogramming somatic cells to pluripotency, which poses
a potential tumor risk that could limit their use in regen-
erative medicine. Adult tissue stem cells can differentiate
into mature cells with specific functions. One obvious
advantage of using adult tissue stem cells is that there
is no ethical issue compared to ES cells, and most import-
antly, certain adult tissue stem cells have multipotency to
differentiate into various kinds of cells for regenerative
medicine.
Spermatogonial stem cells (SSCs) are a subpopulation
of type A spermatogonia in the testis. SSCs were previously
regarded as unipotent stem cells since they were thought
to differentiate into sperm only. However, this concept
has recently been changed. Notably, recent studies have
demonstrated that SSCs from both mouse and human
testes can de-differentiate to become ES-like cells that can
differentiate into various cell lineages of all three embryonic
germ layers [11,12], suggesting that SSCs have important
implications in regenerative medicine. On the other hand,
SSCs de-differentiate to become pluripotent ES-like
cells, which may cause tumor since ES-like cells can form
teratomas after transplantation. Recent study suggests that
SSCs transdifferentiate into prostatic, uterine, and skinepithelium in vivo after transplantation [13]. However, it
remains unknown whether SSCs have the potential to
transdifferentiate into other types of stem cells in vitro. In
this study, we propose a novel concept that SSCs can
directly transdifferentiate to hepatic stem cells in vitro
capable of differentiating into mature hepatocytes, which
achieves two significant endpoints. First of all, direct
transdifferentiation of primary SSCs to hepatic stem cells
without the process of de-differentiation to pluripotent
ES-like cells and embryonic body formation could simplify
the reprogramming procedure. Secondly, our direct
programming of transdifferentiation using growth factors
without gene transduction could be much safer to generate
mature hepatocytes for cell therapy of chronic liver disease
and metabolic abnormalities. Here we present detailed in-
duction and differentiation protocols as well as molecular
and cellular evidence supporting direct transdifferentiation
of SSCs into hepatic stem-like cells that are able to dif-
ferentiate into cells with morphological, phenotypic, and
functional mature hepatocyte-like cells via the activation
of ERK1/2 and Smad2/3 pathways.
Materials and methods
Spermatogonial stem cell line C18-4 cells and culture
Spermatogonial stem cell line, namely C18-4 cells, was
established by transfecting mouse SSCs with a plasmid
expressing the SV40 large T antigen [14]. C18-4 cells were
cultured with Dulbecco’s Modified Eagle’s Medium/Nutri-
ent Mixture F12 (DMEM/F12, Gibico, Grand Island, NY)
supplemented with 10% fetal bovine serum (FBS, Gibico),
2 mM L-glutamine (Invitrogen, Carlsbad, CA), and 100
unit/ml penicillin and streptomycin (Invitrogen). The cells
were passed every 3-4 days and maintained at 34°C in a
humidified 5% CO2 incubator.
Transdifferentiation of SSCs to hepatic stem-like cells and
mature hepatocyte-like cells
Primary SSCs were isolated from the testes of 6-day-old
BALB/c mice using two-step enzymatic digestion and
magnetic activated cell sorting with an antibody to GFRA1
according to procedure as described previously [15]. All
animal care procedures were performed pursuant to the
National Research Council’s Guide for the Care and
Use of Laboratory Animals, China. Experimental protocols
used were approved by the Renji Hospital Animal Care
and Use Committee.
The C18-4 cells and primary SSCs were seeded at
a density of 5,000 cells/well in 24-well plates with
DMEM/F12 containing FBS and the combinations of 2 or
3 growth factors, including Activin A (Peprotech, Rocky
Hills, NJ), Nodal (R&D System, Minneapolis, MN), Wnt3a
(R&D System,), and bFGF (Peprotech). To optimize
transdifferentiation of SSCs to hepatic stem-like cells,
we used 6 culture conditions including the following
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Wnt3a; 3) 50 ng/ml Nodal + 50 ng/ml Wnt3a; iv) 50 ng/ml
Nodal + 50 ng/ml Wnt3a + 20 ng/ml bFGF + liver extract;
v) 50 ng/ml Activin A + 50 ng/ml Wnt3a + liver extract; vi)
50 ng/ml Nodal + 50 ng/ml Wnt3a + liver extract. The best
culture condition for transdifferentiation of SSCs to hepatic
stem-like cells was as follows: DMEM/F12 supplemented
with 0.5% FBS, 50 ng/ml Nodal, 50 ng/ml Wnt3a, and
20 ng/ml bFGF as illustrated in Figure 1A. Various FBS
concentrations, including 0.5%, 2%, and 10%, were used
to optimize the results. When C18-4 cells were seeded
at a density of 104cells/ml, 2% FBS were used for their
proliferation for 2 or 3 days, and FBS concentration wasFigure 1 A novel protocol for transdifferentiation of SSCs to ma
(A) Schematic diagram showed the procedures for inducing SSCs to
Morphology was characterized for SSCs (B), hepatic stem-like cells (C
Scale bars in B, C, D, and E = 50 μm. (F-G) Ultrastructure of hepati
Note: mitochondria (Mi), endoplasmic reticulum (Er), lysosome (Ly), G
bars in F and G= 2 μm.reduced to 0.5% to restrain the overgrowth of C18-4 cells.
For transdifferentiation assays, the medium was refreshed
every 2 days and the cells were cultured for 10 days.
For further differentiation, transdifferentiated cells were
cultured on 0.1% gelatin-coated tissue culture dishes with
hepatocyte culture medium (HCM) plus EGF supplement
(BD Bioscience, Bedford, MA) and 20 ng/ml hepatocyte
growth factor (HGF, Peprotech). Medium was changed
every 2 days and the cells were cultivated for 5 days. The
differentiated cells were matured for another 5-10 days
using HCM supplemented with 10 ng/ml HGF, 10 ng/ml
Oncostain M (OSM, Peprotech), and 10-4 mM dexametha-
sone (Dex, Sigma-Aldrich, St. Louis, MO).ture hepatocyte-like cells and their morphological features.
transdifferentiate to mature hepatocyte-like cells. (B-E)
), small hepatocytes (D), and mature hepatocyte-like cells (E).
c stem cells (F) and mature hepatocyte-like cells (G) from SSCs.
olgi apparatus (Go), and chromatin (Ch), nucleus (Nu). Scale
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Hepatic stem-like cells and mature hepatocyte-like cells
derived from SSCs were fixed in 2.5% w/v glutaraldehyde
in 0.1 M cacodylate buffer. After extensive washing in
PBS, the cells were post-fixed in 1% w/v OsO4 for 30 min,
dehydrated in a graded solution of ethanol and embedded
in Epon. Ultrathin sections were cut and examined under
an electron microscope after staining with uranyl acetate
and lead citrate.
Immunocytochemistry
Immunocytochemistry was performed on SSCs, the
transdifferentiated cells, and the fully differentiated cells
according to the procedure described previously [16]. The
cells were fixed with 4% paraformaldehyde and perme-
abilized in 0.4% triton-X 100 (Sigma-Aldrich) for 15 min.
After washing with phosphate-buffered saline (PBS, Gibico),
cells were blocked in 1% bovine serum albumin (BSA,
Sigma-Aldrich) for 15 min and followed by incubation with
primary antibodies at a dilution with 1:100 overnight at 4°C.
Primary antibodies used were anti-VASA (Santa Cruz
Biotechnology Inc., Santa Cruz, CA), anti-RET (Santa Cruz),
anti-UCHL1 (BD Bioscience), anti-GFRA1 (Santa Cruz),
anti-OV6 (R&D System), anti-CYP1A2 (Santa Cruz), anti-
ALB (Novus Biologicals, Littleton, CO), anti-PLZF (abcam,
Cambridge, MA), anti-SSEA-1(Chemicon, Temecula, CA),
anti-SSEA-4 (Chemicon), anti-Nanog (Chemicon), or anti-
TRA-1-81(Chemicon). After three washes with PBS,
the cells were incubated with the secondary antibody,
including FITC-conjugated or rhodamine-conjugated IgG
(Jackson ImmunoResearch, West Grove, PA), at a 1:200
dilution for 45 min at room temperature. DAPI (4′-6-
diamidino-2-phenylindole) was used to stain the nuclei,
and the cells were observed for epifluorescence using
fluorescence microscope (Nikon Eclipse Ti-S, Nikon Cor-
poration, Tokyo, Japan). Double staining was performed
to determine whether the cells derived from SSCs were
co-expressing CK19 and CK8 using anti-CK19 (R&D
System) and anti-CK8 (Santa Cruz).
Immunofluorescence was also carried out to deter-
mine the expression changes of phosphorylation of
ERK1/2, Smad2, Stat3, and Akt in the C18-4 cells, the
transdifferentiated cells, and differentiated cells using anti-
bodies against phospho-ERK1/2 (Cell Signaling Technol-
ogy, Inc., Danvers, MA), phospho-Smad2 (Cell Signaling
Technology), phospho-Stat3 (Cell Signaling Technology),
or phospho-Akt (Cell Signaling Technology).
RNA extraction and reverse transcription-polymerase
chain reaction (RT-PCR)
Total RNA was extracted from C18-4 cells, the trans-
differentiated cells, and the fully differentiated cells from
C18-4 cells and primary SSCs using Trizol (Invitrogen).
Reverse transcription (RT) was performed using FirstStrand cDNA Synthesis Kit (Fermentas, Lithuania) and
PCR was performed according to the protocol as described
previously [17]. The forward and reverse primers and PCR
products of the chosen genes, including Cytokine 8 (Ck8),
Ck18, Ck7, Ck19, Cyp1a2, Cyp7a1, hepatocyte nuclear factor
(Hnf)3b, Hnf4a, Albumin (Alb), tyrosine aminotransferase
(Tat), transthyretin (Ttr), Cyclin A, Cyclin B, Cyclin D1,
Cyclin E, CDK1, CDK2, c-fos, Oct-4, and Gapdh were
designed and listed in Additional file 1: Table S1. The PCR
reaction started at 94°C for 5 min and was performed as
follows: denaturation at 94°C for 30 sec, annealing at a
temperature (Tm) as indicated in Additional file 1: Table
S1 for 45 sec, and elongation at 72°C for 45 sec. After 30
cycles, the samples were incubated for an additional 5 min
at 72°C. PCR products were separated by electrophoresis
on 1.2% agarose gels. The gels were exposed to chemilu-
minescence (Chemi-Doc XRS, Bio-Rad, Hercules, CA).
Flow cytometry
Hepatic stem-like cells derived from SSCs in the condi-
tioned medium with or without MEK1 inhibitor PD98059
were first fixed with 1% paraformaldehyde, permeabilized
by permeabilization buffer (eBioscience, San Diego, CA),
and incubated with primary antibody to CK8. After
washes, cells were incubated by FITC-coupled secondary
antibody, and analyses were performed using Accuri C6
flow cytometer (Accuri Cytometers, Ann Arbor, MI) and
Cflow software (Accuri Cytometers). The SSCs-derived
cells without primary antibody but were incubated by
FITC-coupled secondary antibody served as a negative
control.
Western blots
Cells were lysed with RIPA buffer (Santa Cruz) for 30 min
on ice. After 30 min lysis on ice, cell lysates were cleared
by centrifugation at 12,000 g, and the concentration of
protein was measured by BCA kit (Dingguo Company,
China). Ten micrograms of cell lysate from each sample
were used for SDS-PAGE (Bio-Rad Laboratories, Richmond,
CA), and Western blots were performed according to the
protocol we described previously [16]. The chosen anti-
body included CK8, phos-ERK1/2 (Santa Cruz), phos-
Smad2 (Santa Cruz), Smad2/3 (Santa Cruz), cyclin A (Santa
Cruz), cyclin B (Santa Cruz), cyclin D1 (Santa Cruz),
cyclin E (Santa Cruz), and ACTB (beta-actin) (IMGENEX
Corp). After extensive washes in PBS, the blots were
detected by chemiluminescence (Chemi-Doc XRS, Bio-Rad,
Hercules, CA).
Albumin synthesis of hepatocyte-like cells derived from
SSCs by ELISA
Primary mouse hepatocytes were isolated from liver tissues
using 0.03% collagenase IV and 0.025 EDTA and cultured
in William’s E + 100 nM insulin + 15% FBS according to
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from SSCs and the differentiated cells was collected
over 2 days from equivalent numbers of cells. Albumin
production in the medium from the differentiated cells
and primary mouse hepatocytes was determined by mouse
Albumin ELISA Quantitation Kit (Alpha Diagnostic Intl.
Inc, San Antonio, TX) according to the manufacturer’s
instructions. Albumin secretion was normalized to per
105 cells.
Urea assays of hepatocyte-like cells derived from SSCs
After exposure of the cells to 2 mM ammonium chloride
(Sigma-Aldrich) for 24 h, urea productions in the culture
media of SSCs, mature hepatocyte-like cells derived from
SSCs, and primary mouse hepatocytes were measured
using Urea Assay Kit (Biovision, Mountain View, CA).
Fresh culture medium supplemented with 2 mM am-
monium chloride was used as a negative control. Urea
production was expressed as mM urea nitrogen per
105 cells within 24 h.
Uptake and release of indocyanine green (ICG) of
hepatocyte-like cells derived from SSCs
Indocyanine green (ICG) (Sigma-Aldrich) was suspended
in DMSO (Sigma-Aldrich) for a stock at 100 mg/ml and
freshly diluted in HCM to a working concentration of
1 mg/ml. Hepatocyte-like cells derived from SSCs and
primary mouse hepatocytes were incubated with the
diluted ICG for 30 min at 37°C. After extensive washes,
positive foci were counted and photographed under
the microscope, and the cells were returned to HCM
and incubated for 20 h. Release of cellular ICG stain
was examined, and undifferentiated C18-4 cells were used
as a negative control while primary mouse hepatocytes
served as a positive control.
Statistical analysis
All experiments were performed independently at least 3
times. All the values were presented as mean ± SEM,
and statistically significant differences (p< 0.05) between
SSCs and differentiated cells were determined using the
analysis of variance (ANOVA) and a 2-tailed t-test.
Results
Direct transdifferentiation of SSCs to hepatic stem-like cells
We first verified the identity of the C18-4 cells using
various markers for germ cells and SSCs. Immunocyto-
chemistry revealed that C18-4 cells expressed VASA
(Additional file 2: Figure S1A), UCHL1 (Additional file 2:
Figure S1B), GFRA1 (Additional file 2: Figure S1C), and
RET (Additional file 2: Figure S1D), suggesting that the
C18-4 cells are phenotypically SSCs.
To induce the transdifferentiation of C18-4 cells to
hepatic stem-like cells, 6 conditioned media supplementedwith various growth factors and liver tissue extract
(Figure 1A and Additional file 3: Figure S2B-2F) were
employed. Among these culture conditions, the combin-
ation of growth factors, including Nodal, Wnt3a, and bFGF,
was the best approach for inducing the transdifferentiation
of C18-4 cells. Other approaches led to a high death rate
of the cells (Additional file 3: Figure S2C, 2D, and 2F), or
had little effect on transdifferentiation (Additional file 3:
Figure S2B and 2E). The C18-4 cells proliferated rapidly
when cultured with 10% FBS (Additional file 3: Figure
S2A). To avoid cell overgrowth, culture medium was
changed into a low concentration of FBS (0.5-2%) in
DMEM/F12 supplemented with Nodal, Wnt3a, and bFGF
(Figure 1B). After 10 days of culture, the morphology of
cells was obviously changed and became oval and stereo-
scopic in shape (Figure 1C), which is similar to hepatic
oval cells (termed hepatic stem cells). Transmission elec-
tron microscopy revealed that these cells had an ovoid
nucleus with condensed chromatin, a higher ratio of nuclei
to cytoplasm, and few organelles including immature
mitochondria (Mi) and rough endoplasmic reticulum
(Er) (Figure 1F). Compared to mature hepatocytes, oval
cells were relatively small since they had a median diameter
of 8 μm.
We next analyzed phenotypic characteristics of the cells
derived from SSCs at transcriptional and translational
levels in order to clarify their identity. We examined the
gene expressions of hepatocytic and cholangiocytic markers
by RT-PCR analysis. As shown in Figure 2A, the cells
derived from C18-4 cells expressed the transcripts of Ck8
and Ck18, markers for hepatic cells [19], as well as Ck7
and Ck19, hallmarks for bile epithelial cells [19], thereby
demonstrating their bipotency. Notably, the cells derived
from primary SSCs expressed the transcripts of Ck18, Ck7
and Ck19 (Figure 2D), further verifying that SSCs could
be converted to bipotential hepatic stem cells. The expres-
sion of Hnf4a, Alb, Tat, and Ttr was undetected, while
Cyp1a2, Cyp7a1, and Hnf3b transcripts were weakly found
in these cells after 7-10 days of transdifferentiation
(Figure 2B, lanes 2 and 3). Immunocytochemistry further
showed that the cells obtained from C18-4 cells were
strongly positive for OV6, a specific marker for hepatic
stem cells [19,20], (Figure 3A) and ALB (Figure 3C) but
not CYP1A2 (Figure 3B). In contrast, the expression of
germ cell and SSCs markers, including VASA (Additional
file 4: Figure S3A), RET (Additional file 4: Figure S3B),
and PLZF (Additional file 4: Figure S3D), was undetectable
in the cells derived from SSCs, while GFRA1 expression
was remarkably reduced in these cells (Additional file 4:
Figure S3C) compared to SSCs (Additional file 2: Figure
S1C). Significantly, the expression of ES cell markers
including SSEA-1 (Additional file 5: Figure S4A), SSEA-4
(Additional file 5: Figure S4B), Nanog (Additional file 5:
Figure S4C), and TRA-1-80 (Additional file 5: Figure S4D),
Figure 2 Transcriptional characteristics of transdifferentiation
of SSCs into hepatic stem-like cells and hepatocyte-like cells.
(A) RT-PCR revealed mRNA expression of Ck8, Ck18, Ck7, and Ck19 in
hepatic stem-like cells derived from SSCs. (B) RT-PCR showed the
transcripts of Ck8, Ck18, Cyp1a2, Cyp7a1, Hnf3b, Hnf4a, Alb, Tat, and
Ttr in SSCs (lane 1), SSC induction for 7 days (lane 2), SSC induction
for 10 days (lane 3), small hepatocytes (lane 4), and mature
hepatocyte-like cells (lane 5) derived from SSCs. The expression of
these genes in liver tissues of adult mice (lane 6) was used as
positive controls. (C) The transcription of Ck8, Ck18, and Ck7 in
mature hepatocyte-like cells derived from SSCs. Gapdh was used as
loading controls of total RNA. (D) The transcription of Ck18, Ck7 and
Ck19 in the cells derived from primary mouse SSCs. Gapdh was used
as loading controls of total RNA. (E) RT-PCR showed the transcripts
of Ck8, Ck18, Cyp1a2, Cyp7a1, Hnf3b, Hnf4a, Alb, Tat, and Ttr in mature
hepatocyte-like cells derived from primary SSCs. Gapdh was used as
loading controls of total RNA.
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cating that these cells didn’t convert to ES cells. Double
staining, using antibodies against CK8 and CK19, revealed
that the cells generated from SSCs were co-expressing
CK8 and CK19 (Figure 3D). Furthermore, the cells gener-
ated from primary mouse SSCs expressed ALB (Figure 3F)
and were co-expressing CK8 and CK19 (Figure 3G).
Collectively, these results suggest that SSCs could trans-
differentiate into hepatic stem-like cells phenotypically.
Notably, flow cytometry showed that over 97% of the cells
derived from SSCs were positive for CK8 (Figure 3E,
left panel), reflecting a rather high transdifferentiation
efficiency of SSCs to hepatic stem-like cells. In contrast,
only 70.9% of cells derived from SSCs were positive forCK8 when SSCs were pretreated with ERK1/2 upstream
inhibitor PD98059 (Figure 3E, right panel), indicating that
ERK1/2 signaling is involved in the transdifferentiation of
SSCs to hepatic stem-like cells.
Differentiation of SSCs-derived hepatic stem-like cells into
small hepatocytes
After 10 days of transdifferentiation, the number of cells
became double or triple compared to the cells seeded. We
next induced the differentiation of hepatic stem-like cells
derived from SSCs using HCM and HGF. Morphological
characteristic is an important means of distinguishing
small hepatocytes from hepatic stem-like cells. Under
phase-contrast microscopy, hepatic stem-like cells derived
from SSCs was changed to become round in shape with a
high ratio of nucleus to cytoplasm (Figure 1D), which was
similar to small hepatocytes. We also examined phenotypic
characteristics of the cells derived from hepatic stem-like
cells in order to probe their identity. As shown in Figure 2B,
lane 4, the cells derived from hepatic stem-like cells
expressed Ck8, Ck18, Cyp7a1, Hnf3b, and Alb transcripts
at high levels, whereas Ck19 transcripts were significantly
reduced in these cells (Additional file 6: Figure S5A, lane
4), implicating that these cells possess the characteristics
of small hepatocytes in phenotypes. Immunocytochem-
istry further revealed that the cells derived from hepatic
stem-like cells strongly expressed ALB (Figure 4A) and
had weak expression of CYP1A2 (Figure 4B). Double
staining using antibodies against CK8 and CK19 revealed
that the cells derived from hepatic stem-like cells expressed
CK8 but not CK19 (Figure 4C). Together, our data im-
plicate that hepatic stem-like cells derived from SSCs
differentiate into small hepatocytes morphologically and
phenotypically.
Differentiation of SSCs-derived hepatic stem-like cells into
mature hepatocyte-like cells
Hepatic stem cells are defined in part by their ability to
differentiate into mature hepatocytes. We made endeavors
to further induce the differentiation of hepatic stem-like
cells derived from SSCs using HCM supplemented with
HGF, OSM, and Dex. In morphology, small hepatocytes
derived from SSCs changed to become polygonal ap-
pearance with tight cell-cell contacts and a low ratio of
cellular nucleus to cytoplasm (Figure 1E), which showed
an attribute of mature hepatocytes. In addition, our ultra-
structural observations provided more convincing evi-
dence that small hepatocytes further differentiated into
mature hepatocyte-like cells since they contained well-
developed organelles such as mitochondria (Mi), endo-
plasmic reticulum (Er), lysosome (Ly) and Golgi apparatus
(Go) (Figure 1G).
We probed phenotypic characteristics of the fully differ-
entiated cells derived from C18-4 cells and primary SSCs
Figure 3 (See legend on next page.)
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Figure 3 The expression of OV6, CYP1A2, ALB, CK8, and CK19 of hepatic stem-like cells derived from transdifferentiation of SSCs.
(A-D) Immunocytochemistry showed protein expression of OV6 (A), CYP1A2 (B), ALB (C), as well as co-expression of CK8 and CK19 (D) in
transdifferentiated cells derived from C18-4 cells. Scale bars in A, B, C, and D = 20 μm. (E) Flow cytometry showed expression of CK8 in the
transdifferentiated cells derived from C18-4 cells in the conditioned medium without PD98059 (left panel) or with PD98059 (right panel). (F-G)
Immunocytochemistry showed protein expression of ALB (F) as well as co-expression of CK8 and CK19 (G) in transdifferentiated cells derived
from mouse primary SSCs. Scale bars in F and G = 20 μm.
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Figure 2B, lane 5, and Figure 2E, the cells derived from
C18-4 cells and primary SSCs had strong mRNA expression
of Ck8, Ck18, Cyp7a1, Hnf4a, Hnf3b, Alb, Tat, and Ttr,
whereas Ck7 transcript was undetected in these cells
(Figure 2C), reflecting that they possess the characteristics
of mature hepatocytes in phenotypes. Immunocytochem-
istry further revealed that the fully differentiated cells
derived from SSCs expressed ALB (Figure 5A) and CYP1A2
(Figure 5B) at high levels. Double staining, using antibodies
against CK8 and CK19, showed that these cells derivedFigure 4 Translational characterization of small hepatocytes derived f
(A), CYP1A2 (B), as well as co-expression of CK8 and CK19 (C) in small hepfrom SSCs had strong expression of CK8 but not CK19
(Figure 5C). Considered together, our results implicate that
the fully differentiated cells derived from SSCs differentiate
into mature hepatocyte-like cells with morphologic and
phenotypic features.
Functional assays of mature hepatocyte-like cells derived
from SSCs
We measured albumin synthesis, urea production, and
indocyanine green (ICG) uptake and release to determine
whether SSCs-derived cells with the morphologicalrom SSCs. (A-C) Immunocytochemistry displayed expression of ALB
atocytes derived from SSCs. Scale bars in A, B, and C = 20 μm.
Figure 5 Characterization of mature hepatocyte-like cells derived from SSCs. (A-C) Immunocytochemistry showed expression of ALB (A),
CYP1A2 (B), as well as co-expression of CK8 and CK19 (C) in mature hepatocyte-like cells derived from SSCs. Scale bars in A, B, and C = 50 μm.
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functional attributes of hepatocytes. Albumin production
is a specific test for the presence and metabolic activity of
hepatocytes. ELISA showed that the differentiated cells
from SSCs synthesized albumin (0.773 ± 0.0247 mg/ml/
105cells) (Figure 6A), which was comparable to albumin
production of mouse primary hepatocytes (Figure 6A).
Urea production is another characteristic of hepatocytes’
activity. Urea assay revealed that the differentiated cells
from SSCs produced urea (0.217 ± 0.0188 mM/105cells)
(Figure 6B), which was lower than urea production of
mouse primary hepatocytes (Figure 6B). Excretion of
endogenous and exogenous compounds from the circula-
tion is a major function of liver, and thus we examined this
function in the SSCs-derived hepatocyte-like cells using
ICG assay. As shown in Figure 6, ICG-positive signal was
clearly seen in the cells derived from SSCs (Figure 6C),
whereas ICG uptake was not detectable in the SSCswithout treatment (Figure 6E). Cell counts indicated that
about 40% SSCs-derived cells were positive for ICG. Fur-
thermore, the ICG uptake in the SSCs-derived hepatocyte-
like cells was excreted by 20 h after removal of ICG from
culture medium (Figure 6D). Interestingly, the uptake and
release of ICG from SSCs-derived hepatocyte-like cells
(Figure 6C and D) was similar to those of mouse primary
hepatocytes (Figure 6F-G).
ERK1/2 and Smad2/3 but not Akt signaling pathways
were activated during the transdifferentiation of SSCs
into mature hepatocyte-like cells
To gain novel insights into the molecular mechanisms
underlying the transdifferentiation of SSCs into mature
hepatocyte-like cells, we analyzed what signaling pathways
were activated. Compared to the control (Figure 7A,
panel i), ERK1/2 phosphorylation was enhanced remarkably
in hepatic stem-like cells (Figure 7A, panel ii), small
Figure 6 Albumin synthesis, urea productions, and cellular uptake and release of ICG of mature hepatocyte-like cells derived from
SSCs. (A) ELISA showed albumin synthesis of SSCs (lane 1), mature hepatocyte-like cells derived from SSCs (lane 2), and primary hepatocytes
(lane 3). “*” indicated statistically significant differences (p< 0.05) between SSCs and mature hepatocyte-like cells derived from SSCs or primary
hepatocytes. (B) Urea assay displayed urea production of SSCs (lane 1), mature hepatocyte-like cells derived from SSCs (lane 2), and primary
hepatocytes (lane 3). “*” indicated statistically significant differences (p< 0.05) between SSCs and mature hepatocyte-like cells derived from SSCs
or primary hepatocytes. (C-G) Cellular uptake (C) and release (D) of ICG in mature hepatocyte-like cells derived from SSCs, uptake of ICG in SSCs
(E), as well as uptake (F) and release (G) of ICG in mouse primary hepatocytes. Scale bars in C-G = 50 μm.
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like cells derived from SSCs (Figure 7A, panel iv). Western
blots further revealed that ERK1/2 phosphorylation was in-
creased in hepatic stem-like cells and mature hepatocyte-
like cells derived from SSCs compared with SSCs
(Figure 7B).
In comparison to the control (Figure 8A, panel i), phos-
phorylation of Smad2 was elevated in hepatic stem-like
cells (Figure 8A, panel ii), small hepatocytes (Figure 8A,
panel iii) and mature hepatocyte-like cells (Figure 8A,
panel iv) derived from SSCs. Additionally, phosphorylation
of Stat3 was slightly increased in hepatic stem-like cells(Figure 8B, panel i) and small hepatocytes (Figure 8B,
panel ii) but not in mature hepatocyte-like cells (Figure 8B,
panel iv) derived from SSCs. Western blots further revealed
that phosphorylation of Smad2 was enhanced in hepatic
stem-like cells and mature hepatocyte-like cells compared
with SSCs (Figure 8C). In direct contrast, phosphorylation
of Akt was not detected in hepatic stem-like cells, small
hepatocytes, or mature hepatocyte-like cells derived from
SSCs (data not shown). These data suggest that ERK1/2
and Smad2 but not Akt signaling pathways contribute in-
structively to the transdifferentiation of SSCs into mature
hepatocyte-like cells.
Figure 7 Expression of ERK1/2 phosphorylation, c-fos transcription and cell cycle proteins in SSCs as well as in hepatic stem-like cells
and mature hepatocyte-like cells derived from SSCs. (A) Immunocytochemistry revealed the expression of phosph-ERK1/2 in SSCs (Panel i),
hepatic stem-like cells derived from SSCs (Panel ii), small hepatocytes derived from SSCs (Panel iii), and mature hepatocyte-like cells derived from
SSCs (Panel iv). Scale bars in A = 50 μm. (B) Western blots showed the expression of ERK1/2 phosphorylation in SSCs (lane 1), hepatic stem-like
cells derived from SSCs (lane 2), and mature hepatocyte-like cells derived from SSCs (lane 3). The expression of ERK2 was used as a loading
control of total proteins. (C) RT-PCR revealed the transcription of c-fos mRNA in SSCs (lane 1), hepatic stem-like cells derived from SSCs (lane 2),
and mature hepatocyte-like cells derived from SSCs (lane 3). Housekeeping gene Gapdh served as a loading control of total RNA. (D) RT-PCR
displayed mRNA expression of cyclin A, cyclin B, cyclin D1, and cyclin E in SSCs (lane 1), hepatic stem-like cells derived from SSCs (lane 2), and
mature hepatocyte-like cells derived from SSCs (lane 3). Gapdh was used as loading control of total RNA. (E) RT-PCR showed transcripts of CDK1
and CDK2 in SSCs (lane 1), hepatic stem-like cells derived from SSCs (lane 2), and mature hepatocyte-like cells derived from SSCs (lane 3). Gapdh
served as loading control of total RNA. (F) Western blots revealed the expression of cyclin A, cyclin B, cyclin D1, and cyclin E in SSCs (lane 1),
hepatic stem-like cells derived from SSCs (lane 2), and mature hepatocyte-like cells derived from SSCs (lane 3). The expression of ACTB was used
as a loading control of total proteins.
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Figure 8 Expression of Smad2-, and Stat3- phosphorylation and Oct-4 in SSCs, hepatic stem-like cells, small hepatocytes, and mature
hepatocyte-like cells. (A) Immunocytochemistry revealed expression of Expression of phosph-Smad2 in SSCs (Panel i), hepatic stem-like cells
(Panel ii), small hepatocytes (Panel iii), and mature hepatocyte-like cells (Panel iv). (B) Expression of phosph-Stat3 in SSCs (Panel i), hepatic stem-
like cells (Panel ii), small hepatocytes (Panel iii), and mature hepatocyte-like cells (Panel iv). Scale bars in A-B = 50 μm. (C) Western blots showed
the expression of phosph-Smad2 in SSCs (lane 1), hepatic stem-like cells (lane 2), and mature hepatocyte-like cells (lane 3). (D) RT-PCR revealed
Oct-4 expression in SSCs (lane 1), hepatic stem-like cells (lane 2), and mature hepatocyte-like cells (lane 3).
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transdifferentiation of SSCs into mature hepatocyte-like cells
We also probed the c-fos transcript when SSCs trans-
differentiated into mature hepatocyte-like cells. RT-PCR
analysis showed that c-fos mRNA was increased significantly
in mature hepatocyte-like cells derived from SSCs com-
pared to hepatic stem-like cells or SSCs (Figure 7C),
suggesting that c-fos transcript is activated during the
transdifferentiation of mouse SSCs into mature hepatocyte-
like cells. Oct-4 transcript was reduced in hepatic stem-like
cells compared to SSCs (Figure 8D), whereas it was en-
hanced in mature hepatocyte-like cells derived from SSCs
compared to hepatic stem-like cells (Figure 8D).Cyclin A, cyclin B, and cyclin E but not cyclin D1, CDK1, or
CDK2 were inactivated during the transdifferentiation of
SSCs into mature hepatocyte-like cells
We further explored the cyclin A, cyclin B, cyclin D1,
cyclin E, CDK1 and CDK2 transcripts, as well as cyclin
A, cyclin B, cyclin D1 and cyclin E proteins when SSCs
transdifferentiated into mature hepatocyte-like cells.
RT-PCR analysis revealed that mRNA of cyclin A, cyclin
B and cyclin E was reduced significantly in mature
hepatocyte-like cells derived from SSCs compared to
hepatic stem-like cells or SSCs (Figure 7D), whereas
there is no significant change in the transcripts of cyclin
D1, CDK1, and CDK2 (Figure 7D and E). Western blots
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proteins but not cyclin D1 protein were diminished in
mature hepatocyte-like cells or hepatic stem-like cells
derived from SSCs compared to SSCs (Figure 7E). Consid-
ered together, these data implicate that cyclin A, cyclin B,
and cyclin E but not cyclin D1, CDK1, or CDK2 are
inactivated when mouse SSCs transdifferentiate into
mature hepatocyte-like cells.
Discussion
Lack of mature hepatocytes limits their wider application
of hepatocyte transplantation and tissue engineering for
the treatment of liver diseases. It is imperative to generate
mature and functional hepatocytes independent of donor
liver organs and from stem cells. Several studies have
shown that hepatocytes can be generated from ES cells [7]
and hepatic stem cells [6]. Recently, human iPS cells have
been used to differentiate into hepatocytes [9,10]. However,
hepatocytes derived from human iPS cells involve a com-
plicated process. Of great concern, the use of iPS cells for
cell therapies is hampered by their tumor-forming risk,
due to reprogramming of somatic cells by gene transfer
using viral vectors and their genetic instability. Therefore,
more attention has been paid to generate hepatocytes
from extra-liver source and adult stem cells. Here we have
for the first time demonstrated that SSCs can directly
transdifferentiate in vitro into the cells withFigure 9 Schematic diagram demonstrated the transdifferentiation of
signaling pathways. “P” indicated “phosphorylate”; solid arrow denoted “p
“no change”.morphological, phenotypic and functional attributes of
mature hepatocyte-like cells.
We have previously identified the C18-4 cells as SSCs
[16,17]. Here we further verified the identity of SSCs using
a variety of markers for germ cells and SSCs. VASA has
been recognized as a germ cell marker [21] while UCHL1
is a hallmark for spermatogonia [22]. GFRA1 and Ret are
co-receptors for GDNF and markers for SSCs [23,24]. We
found that C18-4 cells expressed VASA, UCHL1, GFRA1,
and Ret. These data together with our previous studies
indicate that C18-4 cells possess phenotypic characteristics
of SSCs.
We used 6 different conditioned media to induce the
transdifferentiation of SSCs. Among them, we optimized
the defined condition with Nodal, Wnt3a, and bFGF for
inducing the transdifferentiation of C18-4 cells into cells
with morphological and phenotypic characteristics of hep-
atic stem-like cells. In morphology and ultrastructure,
these cells derived from C18-4 cells resembled hepatic oval
cells. In phenotypes, the cells derived from SSC line and
primary SSCs expressed Ck8, Ck18, Ck7, and Ck19, and
were co-expressing CK8 and CK19. CK8 and Ck18 are
markers for hepatic cells while Ck7 and CK19 have been
regarded as hallmarks for bile epithelial cells [19]. Moreover,
the cells obtained from SSCs strongly expressed OV6, an
antigen specific for rodent hepatic stem cells [19,20]. Taken
together, these results suggest that the cells generated fromSSCs into mature hepatocyte-like cells and ERK1/2 and Smad2/3
romote”; dotted arrow indicated “inhibit”; dotted line showed
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indicating that they retained the bipotential nature of hep-
atic stem cells. Notably, we found the cells derived from
SSCs didn’t express the ES cell markers, including SSEA-1,
SSEA-4, Nanog, or TRA-1-81, suggesting that these cells
are not reprogrammed to ES cells.
Significantly, Nodal, Wnt3a, and bFGF induce a very
high efficiency of SSC transdifferentiation into hepatic
stem-like cells, as evidenced by our observations that
more than 97% of cells derived from SSCs were positive for
CK18. These growth factors play important roles during
embryogenesis and organogenesis of the liver. Nodal plays
an essential role at the earliest stages of endoderm forma-
tion, and Nodal regulates early endoderm development
in vivo [25]. The Wnt pathway is required for liver growth
and development [26]. Wnt3a promotes endodermal
induction from human iPS cells [9], and it is important for
hepatic cell function. Wnt3a is present at critical stages of
human liver development and it elicits a rapid and effi-
cient cellular progression of iPS cells to hepatic endoderm
[27]. bFGF is secreted by the mesoderm and it is the first
factor that commits the foregut endoderm to form liver
primordium [28]. Mesodermal cytokines induce foregut
specification into hepatic endoderm and followed by FGF
signaling into the liver bud [29,30]. This is the first report
showing that Nodal synergized with Wnt3a and bFGF to
induce SSC transdifferentiation into hepatic stem-like cells.
HGF is required for liver development and it is associated
with the ontogenesis of liver [31]. Hepatocyte differenti-
ation can be induced from mesenchymal stem cells by
HGF and other growth factors [32]. Consistent with these
findings, here we found that HGF and HCM could effi-
ciently induce hepatic stem-like cells derived from
SSCs to differentiate into small hepatocytes. Morphologic-
ally and phenotypically different from hepatic stem cells,
small hepatocytes were round and had round nuclei but
did not express CK19. Meanwhile, small hepatocytes
expressed Ck8, Ck18, Cyp7a1, Hnf3b, and Alb transcript,
suggesting that they possess partial characteristics of hepa-
tocytes. HGF promotes hepatic growth and differentiation
while OSM and Dex have been implicated in the matur-
ation of the hepatocytes [32]. Here we found that HGF
acted synergistically with OSM and Dex to effectively in-
duce hepatic stem cells derived from SSCs to differentiate
into cells with morphologic, phenotypic, and functional
features of mature hepatocyte-like cells. In morphology,
these cells became polygonal with a low nucleus/cyto-
plasm ratio. In phenotypes, these cells derived from C18-4
cells and primary SSCs expressed numerous hepatocyte
markers, including CK8, Ck18, Cyp7a1, Hnf4a, Hnf3b,
ALB, CYP1A2, Tat, and Ttr, but were negative for CK19
or Ck7, hallmarks for bile epithelial cells. Of great interest
are our findings that the cells generated from SSCs had
the functional attributes of mature hepatocyte-like cellssince they could synthesize albumin, produce urea, as well
as uptake and release ICG.
It is unclear what signaling pathways are involved
in cellular transdifferentiation. ERK1/2 and Smad2 path-
ways regulate a variety of cellular functions, including cell
proliferation, differentiation, and cell cycle progression
[16,17]. We found that ERK1/2 and Smad2 but not Akt
signaling pathways were activated during the trans-
differentiation of SSCs into mature hepatocyte-like
cells, which offers a novel insight into the mechanisms
underlying liver development and stem cell reprogram-
ming. The ability to transdifferentiate SSCs using patients’
own adult testis tissues directly into hepatic stem cells with-
out having to go through de-differentiation to pluripotent
ES-like cells and embryonic body formation is essential
for reducing differentiation procedures and improving
safety for their clinical applications. Our study not only
outlines novel approaches for transdifferentiation of hep-
atic stem-like cells with high efficiency but also offers new
methods for rapidly and directly differentiating hepatic
stem cells into mature and functional hepatocyte-like cells,
using only growth factors without genetic manipulation. As
such, the approaches presented here could contribute to
overall objective of using patient-specific SSCs to generate
mature and functional hepatocytes for cell transplantation
and tissue engineering for the treatment of liver-related
diseases as well as for hepatotoxicity screening of pharma-
ceutical drug development.
Conclusion
In summary, we have for the first time demonstrated that
SSCs have a greater plasticity to directly transdifferentiate
into hepatic stem-like cells capable of differentiating into
the cells with morphology, phenotypes and function of
mature hepatocyte-like cells through the ERK1/2 and
Smad2/3 signaling pathways and the inhibition of cyclin
A, cyclin B and cyclin E (Figure 9). This study thus sheds
novel insights into molecular mechanisms of stem cell
reprogramming and liver development. Significantly,
mature hepatocytes generated from a patient’s own
SSCs could avoid immunological rejection. This study
provides a novel strategy to generate mature and functional
hepatocytes for cell therapies for liver diseases and drug
toxicology screening.
Additional files
Additional file 1: Table S1. Primers sequences used for RT-PCR.
Additional file 2: Figure S1. Phenotypic characterization of the C18-4
cells. Immunocytochemistry showed expression of VASA (A), UCHL1 (B),
GFRA1 (C), and RET (D) in the C18-4 cells. Scale bars in A, B, C, and
D = 50 μm.
Additional file 3: Figure S2. Morphological features of the cells
derived from SSCs when cultured with various conditioned medium.
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http://www.biosignaling.com/content/11/1/67Phase-contrast microscopy revealed the morphology of the cells from
SSCs cultured with 10% FBS (A), 50 ng/ml Activin A + 50 ng/ml Wnt3a
(B), 50 ng/ml Nodal + 50 ng/ml Wnt3a (C), 50 ng/ml Nodal + 50 ng/ml
Wnt3a + 20 ng/ml bFGF + liver extract (D), 50 ng/ml Activin A + 50 ng/ml
Wnt3a + liver extract (E), and 50 ng/ml Nodal + 50 ng/ml Wnt3a + liver
extract (F). Scale bars in A-F = 50 μm.
Additional file 4: Figure S3. Phenotypic characterization of the cells
derived from C18-4 cells. Immunocytochemistry showed expression of
VASA (A), RET (B), GFRA1 (C), and PLZF (D) in the cells generated from
C18-4 cells. Scale bars in A, B, C, and D = 50 μm.
Additional file 5: Figure S4. Phenotypic characterization of the cells
derived from C18-4 cells. Immunocytochemistry showed expression of
SSEA-1 (A), SSEA-4 (B), Nanog (C), and TRA-1-81 (D) in the cells generated
from C18-4 cells. Scale bars in A, B, C, and D = 50 μm.
Additional file 6: Figure S5. Ck19 transcript and CK8 protein expression
in SSCs, hepatic stem-like cells, small hepatocytes derived from SSCs. (A)
RT-PCR revealed mRNA expression of Ck19 in SSCs (lane 1), SSC induction for
7 days (lane 2), SSC induction for 10 days (lane 3), and small hepatocytes
(lane 4). (B) Western blots showed CK8 expression in mature hepatocyte-like
cells derived from SSCs (lane 1), SSCs (lane 2), and small hepatocytes derived
from SSCs (lane 3). ACTB served as a loading control of total proteins.
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